**INTRODUCTION**

Beta-lactam antibiotics are among the most commonly used antimicrobials in the world. Extended-spectrum beta-lactamases (ESBLs) are clavulanate susceptible enzymes that hydrolyze penicillins, expanded-spectrum cephalosporins, and monobactams and are commonly inhibited by beta-lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam [1]. Ambler Class C (AmpC) beta-lactamases are cephalosporinases that are poorly inhibited by clavulanic acid. They can be differentiated from ESBLs by their ability to hydrolyze cephamycins as well as other extended-spectrum cephalosporins [2]. The rapid emergence of Gram-negative bacteria coproducing ESBL and AmpC beta-lactamase pose a challenge in therapeutics, as they mask each other, making their detection difficult. They also cause an increase in the minimum inhibitory concentrations (MIC) of beta-lactam antibiotics and create limitations in the selection of antimicrobial agents [3].

Skin and soft-tissue infections (SSTIs) are the general term used for infections of the entire skin layer, including the subcutaneous and muscle tissue layers and their respective fascia structures. In India, SSTIs may contribute to longer hospital stays, increase the cost of medical care, and play an important role in the development of antimicrobial resistance [4]. Increasing resistance to the beta-lactam group of antibiotics by the Gram-negative pathogens has led to the search of new antimicrobials, from natural products and secondary metabolites of the medicinal plants. After the substantiation of pharmacological effects, medicinal plants can act as natural sources for compounds that could be effective as new antimicrobial agents.

**Azadirachta indica** (neem) belongs to Meliaceae family and is a very important medicinal plant which is traditionally used to treat different diseases. Almost every part of the tree has been used in traditional system of medicine for the treatment of a variety of human ailments. It has remarkable anti-inflammatory, antibacterial, and antifungal properties [5]. It has been found that neem includes a vast array of biologically active compounds that are chemically diverse and structurally complex. More than 140 compounds have been isolated from different parts of neem. The antibacterial activity of neem might be due to the presence of triterpenoids - bitters, phenolic compounds, camenitoids, steroids, and tetratriterpenoids - azadirachtin [6].

This study aims to investigate the antibacterial activity of methanolic neem leaf (NLM) extract against lactose fermenting coproducers of ESBL and AmpC isolated from SSTIs.

**METHODS**

The present study was conducted in a tertiary care hospital and was approved by the local ethics committee of the institution.

**Bacterial strains**

A total of 88 non-duplicate lactose fermenting strains isolated from SSTIs of patients from our tertiary care hospital were selected for the study. The samples were processed, and the isolates were identified as per standard laboratory methods [7].

**Antimicrobial susceptibility test (AST)**

The antimicrobial susceptibility was determined by Kirby-Bauer disk diffusion method in accordance with the Clinical and Laboratory...
Standards Institute (CLSI) guidelines using commercially available antimicrobial discs (HiMedia, Mumbai, India) [8]. The following antibiotics were used - ampicillin (10 μg), amikacin (10 μg), ciprofloxacin (5 μg), gentamicin (10 μg), amoxiclav (30 μg), ceftazidime (30 μg), cefoxitin (30 μg), imipenem (10 μg), and piperacillin-tazobactam (100/10).

The turbidity of the isolates was adjusted to 0.5 McFarland standards for all the tests. All the isolates which were resistant to ceftazidime and cefotaxime, as per the CLSI susceptible breakpoints were further screened for confirmation of ESBL and AmpC production.

**Phenotypic confirmatory disc diffusion test (PCDDT)**

The current CLSI guideline does not describe any method for detection of isolates producing AmpC beta-lactamases. Ceftazidime (30 μg) - ceftazidime/clavulanic acid (30/10, HiMedia, Mumbai, India) was used for ESBL detection. If there was ±5 mm increase in the inhibition zone diameter of ceftazidime/clavulanic acid versus ceftazidime alone, the isolate was considered as an ESBL producer [8]. Cefotixin (CX 30μg) - Cefotixin/Cloxacillin (30/200, HiMedia, Mumbai, India) discs were used for AmpC detection. An increase of ≥4 mm in the inhibition zone diameter of cefotixin/cloxacillin acid versus cefotixin alone indicated AmpC production [9].

**E-test**

Detection by phenotypic testing may be misleading, especially when there is a coexistence of ESBL and AmpC. They mask each other, which results in misreporting and failure in the clinical treatment of patients. For this reason, E-strips which differ from conventional strips have been used. Different inhibitors have been applied to improvise the phenotypic tests for beta-lactamase detection.

ESBL and AmpC detection Ezy MIC™ strip (EM081, HiMedia, Mumbai, India) are drug-impregnated strips in which upper half contains a concentration gradient of four antibiotics; ceftazidime, cefotaxime, cepime, and cloxacillin plus clavulanic acid and tazobactam and lower half contains of ceftazidime, cefotaxime, cepime, and cloxacillin in a concentration gradient in a reverse direction. The isolates were reported and confirmed as ESBL and AmpC beta-lactamase producer as per the application sheet supplied by the manufacturer. These strips are to be used along with pure ESBL detection strips (EM079 HiMedia, Mumbai, India) to avoid false positive results [8-11].

A standard reference strain of *Escherichia coli* ATCC 25922, susceptible to all antimicrobial drugs tested, and positive control strain *Klebsiella pneumoniae* ATCC 700605 was used as a quality control for AST, confirmatory phenotypic disc diffusion test, and the E-test, as per CLSI guidelines. These phenotypically confirmed coproducers of ESBL and AmpC were selected as test strains, for further studies.

**Preparation of NLM extract**

Fresh *A. indica* leaves were purchased from the local market. The collected leaves were identified and authenticated by a Botanist at K.C. College, Mumbai. The leaves were separated, washed, and dried in shade. 10 grams of dried and ground leaves were transferred into a flask containing 150 ml of methanol and Soxhlet extraction was carried out. The extract was filtered and the solvent was evaporated. The dried extract containing 150 ml of methanol and Soxhlet extraction was carried out. 10 grams of dried and grounded leaves were transferred into a flask and added with 900 ml of HPLC grade water and add 0.5 ml of orthophosphoric acid. Make up the total volume to 1000 ml with HPLC grade water, filter through 0.45 μ membrane and degas in a sonicator for 3 min (Natural Remedies, Bangalore, India).

**Antibacterial activity of NLM extract**

The evaluation of antibacterial activity of NLM was conducted by the disc diffusion method using Mueller-Hinton agar as described by the CLSI [8]. Sterile paper discs (6 mm, HiMedia, Mumbai, India) were impregnated with 20 μl of the 500 mg/ml NLM extract and placed on the inoculated agar. For the positive control, a disc of imipenem (10 μg) and for negative control, a disc impregnated with DMSO was placed on the inoculated Mueller-Hinton agar. The plate was incubated at 37°C for 24 h. The experiment was performed in triplicate [13].

**Determination of MIC**

The MIC of NLM extract was determined by agar dilution method [14]. For MIC of NLM extract, dilutions were prepared by mixing NLM extract with sterile Mueller-Hinton agar to get final concentrations ranging between 0.25% and 8% (2.5-80 mg/ml). A plate of Mueller-Hinton agar with DMSO served as a control. These plates were seeded with bacterial suspensions and were incubated at 37°C for 24 h. The MIC was recorded as the lowest concentration of NLM extract at which visible bacterial growth was completely inhibited. The experiment was performed in triplicate [13,14].

Using the Student’s t-test, significance of the difference between the mean of zone of inhibition (ZOI) of the NLM extract against *E. coli* and *Klebsiella* spp. was statistically evaluated.

**RESULTS**

Among the 88 lactose fermenting strains isolated from SSTIs, 59 isolates were identified as *E. coli* and 29 as *Klebsiella* spp. Out of the 88 lactose fermenting isolates from SSTIs, 78.4% (69/88) isolates were found to be beta-lactamase producers. Resistance to ceftazidime and cefoxitin was indicative of ESBL and AmpC production, respectively, which was further confirmed by PCDDT and E-test. 42% (37/88) of the isolates were confirmed to be coproducers of ESBL and AmpC, and these were used as test strains further in the study. Among all the 37 test strains, there were 27 *E. coli* and 10 *Klebsiella* spp. isolates. Thus, in the current study, 45% (27/59) of *E. coli* and 34% (10/29) of *K. pneumoniae* isolates were coproducers of ESBL and AmpC producers.

The AST studies of the test strains revealed that carbapenems and aminoglycosides were the most effective antibiotics against the ESBL and AmpC coproducers. All the test strains exhibited a higher resistance rate toward quinolones in comparison with carbapenems and aminoglycosides. Among the two beta-lactamase inhibitors, piperacillin-tazobactam was more effective than amoxyclav against all the test strains. All the coproducers of ESBL and AmpC were also found to be multidrug-resistant, i.e., they were resistant to three or more than three groups of antibiotics (Fig. 1).

The estimation of active ingredient, nimbin was carried out by HPLC analysis and was found to be 0.007% (w/w). Primary screening for *in vitro* antibacterial activity of NLM extract was carried out by disc diffusion method. The extract showed activity against all the 37 lactose fermenting isolates from SSTIs, coproducing ESBL and AmpC. The average ZOI was ≥4 mm in the inhibition zone diameter of cefoxitin/cloxacillin acid versus cefoxitin alone indicated AmpC production [9].

High-performance liquid chromatography analysis (HPLC)

The HPLC system consisted of a Shimadzu LC-2010 CHT model (Shimadzu, Tokyo, Japan), with a C18-packed with silanized octadecylsilica gel, 5 μm size, 250 mm × 4.6 mm (Merck) stainless steel column. 20 μl of the prepared sample was injected into the HPLC column for the analysis. The elution was carried out at a flow rate of 1.2 ml/min using the gradient proportion of 100% acetonitrile and buffer as the mobile phase. For the preparation of buffer, dissolve 0.136 g of anhydrous potassium dihydrogen orthophosphate (KH₂PO₄) in 900 ml of HPLC grade water and add 0.5 ml of orthophosphoric acid. Make up the total volume to 1000 ml with HPLC grade water, filter through 0.45 μ membrane and degas in a sonicator for 3 min (Natural Remedies, Bangalore, India).
The above table depicts the number and percentage of lactose fermenting isolates inhibited by various minimal concentrations of NLM extract (n=37).

Based on ZOI, the difference in antibacterial activity of NLM extract against *E. coli* and *Klebsiella* spp. was statistically insignificant (*P*=0.05). Thus, the antibacterial activity of NLM extract was found to be equivalent for *E. coli* and *Klebsiella* spp. isolates, coproducing ESBL and AmpC from SSTIs.

**DISCUSSION**

Gram-negative bacilli producing multiple beta-lactamases are very complex antibiotic-resistant pathogens to control and treat. The study of the pattern of bacterial resistance in clinical isolates is important for epidemiological and therapeutic purposes. In the current study, the principal mechanism of beta-lactam resistance was found to be coexpression of ESBL and AmpC beta-lactamases in *E. coli* and *Klebsiella* spp. In this study, imipenem was established as the most effective antibiotic for strains which coproduce ESBL and AmpC, followed by aminoglycosides, amikacin, and gentamicin. The resistant rate in the test strains toward third-generation cephalosporins was well-corroborated by a similar study conducted in Mumbai, by Shinde et al. [15]. The prevalence rate of the coproduction of ESBL and AmpC in lactose fermenters was in accordance with the study carried out by Afroz et al. [15]. The prevalence rate in the test strains was higher than the findings of previous studies of Koona and Budida [6] and Chaturvedi et al. [20].

In the recent past, due to the multidrug-resistance exhibited by coproducers of ESBL and AmpC, carbapenems had been the drug of choice for serious infections [17]. In the current study, all the test strains were multidrug-resistant, but were sensitive to carbapenems, justifying their usage in empirical therapy. However, carbapenem-resistant strains are rapidly emerging; suggesting monitored usage of carbapenems in therapeutics. It is a known fact that beta-lactam inhibitors are ineffective against AmpC producers under *in vivo* conditions. Conversely, sometimes, false susceptibility patterns are observed, particularly in incidences of coexpression beta-lactamases, leading to erroneous treatment choices [16]. A significant observation of the existing study was the false susceptibility against piperacillin-tazobactam, *in vitro* by ESBL and AmpC coproducers. This combination would presumably not be effective under *in vivo* conditions for isolates producing AmpC. Thus, this evidence suggests that detection of AmpC along with ESBL producers should be performed routinely in the hospitals, to avoid therapeutic failure.

The increasing failure of antibiotics has led to the screening of several plant extracts for their potential antimicrobial activity. The antimicrobial activity of neem leaves has been majorly attributed to bitters like nimbin, which was found in NLM extract in this study [19]. The antibacterial activity of NLM extract was studied using disc diffusion test, and it inhibited all the test strains indicating a potent antibacterial activity against the resistant isolates. Our results are in agreement with the findings of previous studies of Koona and Budida [6] and Chaturvedi et al. [20].

In the current study, the average MIC of NLM extract against the test strains was higher in comparison to the beta-lactam sensitive isolates selected in the study by Dahiya et al. [21] and Emmanuel et al. [22]. In another previous study reported by Shah et al., the MIC values against pure ESBL and pure AmpC producers were also found to be comparatively lower than the current study [13]. On the basis of above comparisons, it can be suggested that a higher concentration of NLM extract is required for inhibition of ESBL and AmpC coproducers. Thus, the higher MIC values in the current study against the selected test strains may be attributed to multiple beta-lactamase production.

There is a paucity of information on antibacterial activity of neem leaves against coproducers of ESBL and AmpC. To the best of our knowledge, the study of antibacterial activity of neem leaf against coproducer of ESBL and AmpC from SSTIs has not been reported earlier.

**CONCLUSION**

The evidence summarized above, tentatively suggests neem leaves may have the ability to curb the growing menace of antibiotic-resistant bacteria. The *in vitro* study proved that NLM extract inhibited lactose fermenting coproducers of ESBL and AmpC isolated from SSTIs. Further, large-scaled and well-designed clinical trials are required to provide more conclusive proof of antimicrobial efficacy of NLM extract. Additional investigation on neem leaves can increase the isolation of the newer molecules which will be helpful for the treatment of SSTIs.

**ACKNOWLEDGMENT**

The authors are grateful to the Head of the Microbiology Department, the Bacteriology section in charge of Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, and Dr. Sonal D., botanist K.C. College.

**Table 1: MIC of NLM extract against strains coproducing ESBL and AmpC**

<table>
<thead>
<tr>
<th>Concentration of NLM (mg/ml)</th>
<th>30</th>
<th>40</th>
<th>50</th>
<th>60</th>
<th>70</th>
<th>80</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of strains inhibited</td>
<td>-</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>28</td>
<td>-</td>
</tr>
<tr>
<td>Percentage of strains inhibited</td>
<td>10.8</td>
<td>2.7</td>
<td>5.4</td>
<td>5.4</td>
<td>75.7</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

NLM: Methanolic neem leaf, MIC: Minimum inhibitory concentration, ESBL: Extended-spectrum beta-lactamase
REFERENCES


